Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy
Sheng Chen(Fudan University Shanghai Cancer Center), Zhi‐Ming Shao(Fudan University)
Cited by 36
Related Papers
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
|Nature Communications|2018|183
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
|Journal for ImmunoTherapy of Cancer|2021|55
Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
|International Journal of Nanomedicine|2015|21